Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Inclusion criteria

• ✓. Sign the Informed Consent Form (ICF) and be able to comply with the visit and related procedures as stipulated in the protocol.
• ✓. Be male or female, aged ≥18 years old.
• ✓. Histologically or cytologically confirmed primary non-small cell lung cancer (NSCLC).
• ✓. Clinical stage IB to IIIA disease, according to the 8th edition of the TNM classification for lung cancer as defined by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC).
• ✓. All subjects must have a written test report before enrollment to prove the presence of KRAS G12C mutation; and must have no sensitive mutations of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK).
• ✓. The patient is deemed by a thoracic surgeon to be a candidate for curative resection (R0 resection) and has adequate pulmonary function to undergo the planned pulmonary resection.
• ✓. Have at least one measurable lesion according to RECIST 1.1 criteria.
• ✓. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.

Exclusion criteria